In the current study author George Harb http://slimex.biz.

Home / nurse / In the current study author George Harb http://slimex.biz.

In the current study author George Harb http://slimex.biz.

In the current study author George Harb, a postdoctoral researcher in Pitt’s endocrinology division lead developed mice the gene for another cell cycle protein very similar to very similar to pRB than p130 lacking. Again, there was no effect on the beta-cell production http://slimex.biz slimex.biz . The similarity of pRb and p130 indicated that they serve the same purpose, and so his next step deficient mice was similar in both proteins to construct the result was a significant increase in beta – cell replication. A Cancer Gene switch for the repair of damaged DNAScientists uncover the Medical Research Council Laboratory of Molecular Biology, as an important cancer gene repair works by increasing the accuracy with which the broken DNA. Inherit a faulty version of the BRCA1 gene are at higher risk of developing breast or ovarian cancer.

slimex.biz

On CEL-SCI CorporationCEL-SCI Corp. Has development of products, boost your immune. Be main product is Multikine looking statements for a global phase III study in advanced the primary head and neck Krebs being prepared for. CEL-SCI is well as developing a vaccine that to prevent or treat swine flu and any other Grippen having his LEAPS technology platforms and looks forward coming soon stop validation of of its state – of-the-art facility Maryland the she expects for utilize, to and aseptic filling of stem cell research produced therapy and other biological products for. The company has. Branch offices in Vienna, Virginia, and Baltimore, Maryland If used in this report, the words ‘intends,”believes,”anticipates’and ‘expects’and similar terms should to identify forward-looking statements. Such statements involve risks and uncertainties that could cause the actual results may differ materially from those projected. Factors that lead to or contribute to such discrepancies include, the inability the clinical results in clinical trials, timely development of potential products that are be be safe and effective to duplicate, showed ‘s SEC filings, necessary regulatory approvals, difficulties in the manufacturing any of the to the company’s potential products , inability to the necessary funds and that hazard factors that are periodically at CEL-SCI Inc. ‘s SEC filings, of which set to, however does not for his report to Form enhance 10 delimits – C / A for the fiscal year ends 30 September 2008. Which Company accepts no obligation to publicly that result of any revisions to these forward oriented statements that are made for reflecting the events or circumstances subsequent to of the date hereof the occurrence of unanticipated the occurrence of unanticipated event.